Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 14 of 5804
-
Experimental drug aims to halt rare neurological decline
Disease control Not yet recruitingThe purpose of this study is to confirm the treatment effects of vatiquinone on the key measures of FA disease progression.
Phase: PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a Two-Pronged antibody boost chemo against tough lymphomas?
Disease control Not yet recruitingThis phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high grade (double hit) B- cell lymphomas that are newly diagnosed, that has come back after a period of improvement (relapsed) or that does not respond to treatmen…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug cocktail aims to stop leukemia return after transplant
Disease control Not yet recruitingThis study evaluates the efficacy and safety of maintenance therapy with lisaftoclax plus azacitidine after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with acute myeloid leukemia (AML) at high risk of relapse. The main questions this study aims to a…
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a cheaper copy of a leukemia drug work just as well?
Disease control Not yet recruitingA Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Study to Compare the Similarities in Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Injectable BLB101 and Blincyto® in Adult Participants with R/R CD19+ B-ALL. Provide evidence for the approval a…
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could an arthritis drug stop type 1 diabetes before it starts?
Prevention Not yet recruitingThe goal of this clinical trial is to learn if golimumab is effective at preventing progression to Stage 2 diabetes in participants with presymptomatic Type 1 Diabetes. The expected duration of this study is approximately 6 years. Participants will: * Take golimumab or placebo …
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Hope for rare disease: new drug trial for VEXAS syndrome begins
Disease control Not yet recruitingThis study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.
Phase: PHASE2, PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Stem cell transplant or drug combo: which better prevents leukemia return in seniors?
Disease control Not yet recruitingThe researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Double-Barreled drug attack targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThe primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could fewer HPV vaccine doses offer lasting protection?
Prevention Not yet recruitingThis study evaluates the long term protection provided by either one or two doses of the HPV vaccine for patients who were part of the ESCUDDO study.
Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jul 25, 2026 00:00 UTC
-
Nasal spray could offer new hope for Treatment-Resistant depression
Disease control Not yet recruitingThe purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams \[mg\] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant depression (individuals with major depressive disorder …
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Precision genetic therapy aims to slow rare brain disease
Disease control Recruiting nowThis project aims to evaluate the safety and efficacy of precision genetic therapy for patients with Ataxia-telangiectasia (A-T), a rare neurodegenerative disease caused by mutations in the ATM gene. The investigators will conduct a clinical trial to study the safety and efficacy…
Phase: PHASE1, PHASE2 • Sponsor: Timothy Yu • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Lung cancer combo therapy aims to clear tumors before surgery
Disease control Not yet recruitingThis study is an open-label, multicenter phase II clinical trial of adebelizumab combined with other anti-tumor therapies in patients with non-small cell lung cancer. The aim of this study was to evaluate the safety, tolerability and efficacy of adebelizumab combined with other a…
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a new daily pill quiet the immune attack behind psoriasis?
Disease control Not yet recruitingThis study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group. The study aims to evaluate the efficacy and safety of once-…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New shot could tame tough eczema by calming overactive immune cells
Disease control Recruiting nowThis is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall d…
Phase: PHASE3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Brain chip breakthrough: paralysis patients may control devices with thought
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback …
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can a simple screening test at birth save thousands of children with sickle cell disease?
Diagnosis Not yet recruitingThe overarching goal of this study is to evaluate the feasibility of a new methodology that combines three multi-level implementation strategies to optimize the population-level uptake of essential evidence-based, standard of care treatments for infants with sickle cell disease (…
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New cocktail of drugs and vaccines takes on advanced ovarian cancer
Disease control Not yet recruitingThis trial proposes to evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal infusion of a chemokine modulatory (CKM) regimen composed of a co…
Phase: PHASE2 • Sponsor: Kalinski, Pawel, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can a burst of radiation make CAR t-cells fight cancer harder?
Disease control Not yet recruitingThis is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM). The investigators' hypothesis is that the combination will make…
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Heart pump may help High-Risk patients get Life-Saving artery treatment
Disease control Not yet recruitingBased on a multi-center randomized controlled study, this research aims to evaluate the efficacy and safety of interventional therapy supported by the CorVad percutaneous left ventricular assist system (Micro-axial Flow Pump) for patients with complex coronary heart disease (CHD)…
Phase: NA • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Spinal-Fluid vaccine targets breast cancer cells in the brain
Disease control Recruiting nowThe purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), in combination with trastuzumab or nivolumab to confirm the highest dose of the study treatment that can be given safely to participants with Breast Cancer (BC) with Lept…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC